Shuo Liu1,2, Stephen Lee3,4, Prem Rashid5,6, Haider Bangash7,8, Akhlil Hamid7,8, Jason Lau3, Ronald Cohen3,4. 1. Royal Perth Hospital, Perth, WA, Australia. shuo.mark.liu@hotmail.com. 2. Port Macquarie Base Hospital, Port Macquarie, NSW, Australia. shuo.mark.liu@hotmail.com. 3. Uropath Pty Ltd, West Leederville, WA, Australia. 4. Faculty of Medicine and Dentistry, School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, WA, Australia. 5. Port Macquarie Base Hospital, Port Macquarie, NSW, Australia. 6. Faculty of Medicine, Rural Clinical School, University of New South Wales, Sydney, NSW, Australia. 7. Royal Perth Hospital, Perth, WA, Australia. 8. Fiona Stanley Hospital, Perth, WA, Australia.
Abstract
OBJECTIVES: To evaluate the intermediate outcome of conservative management in patients with biopsy-proven oncocytoma. PATIENTS AND METHODS: Patients with oncocytoma diagnosed on percutaneous core biopsy between January 2000 to December 2014 were identified from the renal biopsy database of a large specialist urologic pathology laboratory. After review of patient clinical records, the study cohort comprised only of patients enrolled in active surveillance. Clinicopathological and follow-up details were reviewed for each case, in particular: type and interval of surveillance imaging, tumour growth, definitive intervention and reason for intervention. Where possible, correlation was made between the final surgical and the initial biopsy specimens. RESULTS: Fifty three patients diagnosed with oncocytoma on core biopsy were initially placed on active surveillance with median follow-up of 34 months (range 6-109). The median age at diagnosis was 65 years (range 20-85) and median tumour size was 30 mm (range 13-87). Mean average tumour growth was 1.4 mm per annum (median 0 mm/year) with the majority (36 of 53, 68%) exhibiting minimal growth (less than 2 mm per annum) or partial regression. Forty seven of the 53 patients remained on active surveillance with no significant progression. Six patients elected to undergo definitive intervention (five surgical excision, one ablation). Renal oncocytoma was confirmed in all five patients who underwent surgical excision of their lesions. CONCLUSIONS: The majority of oncocytomas in this study showed minimal growth rate or regression. Patients with biopsy proven oncocytoma can be conservatively managed with active surveillance.
OBJECTIVES: To evaluate the intermediate outcome of conservative management in patients with biopsy-proven oncocytoma. PATIENTS AND METHODS: Patients with oncocytoma diagnosed on percutaneous core biopsy between January 2000 to December 2014 were identified from the renal biopsy database of a large specialist urologic pathology laboratory. After review of patient clinical records, the study cohort comprised only of patients enrolled in active surveillance. Clinicopathological and follow-up details were reviewed for each case, in particular: type and interval of surveillance imaging, tumour growth, definitive intervention and reason for intervention. Where possible, correlation was made between the final surgical and the initial biopsy specimens. RESULTS: Fifty three patients diagnosed with oncocytoma on core biopsy were initially placed on active surveillance with median follow-up of 34 months (range 6-109). The median age at diagnosis was 65 years (range 20-85) and median tumour size was 30 mm (range 13-87). Mean average tumour growth was 1.4 mm per annum (median 0 mm/year) with the majority (36 of 53, 68%) exhibiting minimal growth (less than 2 mm per annum) or partial regression. Forty seven of the 53 patients remained on active surveillance with no significant progression. Six patients elected to undergo definitive intervention (five surgical excision, one ablation). Renal oncocytoma was confirmed in all five patients who underwent surgical excision of their lesions. CONCLUSIONS: The majority of oncocytomas in this study showed minimal growth rate or regression. Patients with biopsy proven oncocytoma can be conservatively managed with active surveillance.
Authors: Michael Baboudjian; Daniel Moser; Takafumi Yanagisawa; Bastien Gondran-Tellier; Eva M Compérat; Damien Ambrosetti; Laurent Daniel; Cyrille Bastide; Shahrokh F Shariat; Eric Lechevallier; Pietro Diana; Alberto Breda; Benjamin Pradere; Romain Boissier Journal: Eur Urol Open Sci Date: 2022-05-19
Authors: Flora E Rodger; Keiran Brown; Steve Leung; Jack Coode-Bate; James Armitage; Anne Warren; Jane Hendry; Grant D Stewart; Alex Laird; Grenville M Oades Journal: BJUI Compass Date: 2022-03-03